For example, GPR40 agonists such as TAK-875 [94], LY2881835 [95], P11187 [96], SHR0534 [97], and JTT-851 [98] have been evaluated in clinical trials for the treatment of type 2 diabetes. This evidence concerns the gene FFAR1 and type 2 diabetes mellitus.